DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Droxia (Hydroxyurea) - Published Studies


Droxia Related Published Studies

Well-designed clinical trials related to Droxia (Hydroxyurea)

Hydroxyurea and growth in young children with sickle cell disease. [2014]

Immunologic effects of hydroxyurea in sickle cell anemia. [2014]

Impact of hydroxyurea on clinical events in the BABY HUG trial. [2012]

Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. [2012]

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. [2012]

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. [2011.12.01]

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. [2011.10.19]

The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. [2011.05]

Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. [2010.12.14]

Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. [2010.12]

The impact of hydroxyurea on career and employment of patients with sickle cell anemia. [2010.11]

Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at Home. [2010.09.21]

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. [2010.06]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. [2010.02]

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. [2010.02]

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. [2010.01.01]

Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. [2010]

The impact of hydroxyurea on career and employment of patients with sickle cell anemia. [2010]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. [2010]

Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. [2009.10]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. [2009.09.03]

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. [2009.08.06]

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. [2008.12]

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. [2007.11]

Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. [2007.07.01]

Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. [2007]

Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. [2006.12]

Hydroxyurea and sickle cell anemia: effect on quality of life. [2006.08.31]

The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). [2006.06]

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. [2005.07.22]

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. [2005.07.07]

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. [2005.04.08]

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. [2005.04]

Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. [2004.08]

Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. [2004.03.05]

A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). [2004.03]

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. [2004]

Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix. [2004]

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. [2003.08]

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. [2003.05]

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). [2003.05]

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. [2003.04.02]

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. [2002.12.06]

The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. [2002.07]

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. [2002.05]

Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. [2002.04.01]

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. [2001.12.01]

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. [2001.07.27]

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. [2000.09.29]

Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-naive patients. [2000.09]

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. [2000.09]

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. [2000.05]

A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. [2000.04]

Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. [2000.02]

A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. [2000.02]

Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals. [1999.10]

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. [1999.05]

Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. [1999.05]

High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. [1998.08]

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. [1998.05.28]

Hydroxyurea for HIV infection. [1998.04]

Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. [1998.03.01]

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. [1998.03.01]

[Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age] [1998.03]

Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. [1998]

Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. [1997.11.01]

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. [1997.10]

An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). [1997.10]

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. [1997.07]

Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. [1997.05]

Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. [1997.04.01]

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. [1997.04]

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. [1997.02.01]

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. [1997.01]

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. [1996.11]

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. [1996.10.01]

Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. [1996.09.15]

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. [1996.05]

Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. [1996.02]

Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. [1995.12]

A preliminary evaluation of hydroxyurea for the treatment of rheumatoid arthritis. [1995.09]

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. [1995.05.18]

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. [1995.04.27]

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. [1994.12.15]

Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. [1994.04]

Experimental therapy of sickle cell disease. Use of hydroxyurea. [1994.02]

[Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980] [1993.12.11]

Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. [1993.08]

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. [1993.07.15]

A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. [1993]

The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. [1993]

[Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies] [1992.11.07]

[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)] [1991.02]

Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study. [1991]

Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer. [1989.10]

A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. [1989.03]

A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study. [1988.07]

[Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897] [1988.02]

Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. [1988.02]

Well-designed clinical trials possibly related to Droxia (Hydroxyurea)

Front-line therapy in polycythemia vera and essential thrombocythemia. [2012]

Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. [2012]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017